Roberto Mignone Sells 77,400 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 77,400 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. The trade was a 17.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Roberto Mignone also recently made the following trade(s):

• On Thursday, November 6th, Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00.

Teva Pharmaceutical Industries Stock Up 0.2%

Shares of NYSE:TEVA opened at $30.39 on Friday. The firm has a market cap of $34.86 billion, a P/E ratio of 50.65, a P/E/G ratio of 1.81 and a beta of 0.67. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $30.56. The business has a fifty day simple moving average of $24.44 and a 200 day simple moving average of $20.04. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wall Street Zen cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 13th. Scotiabank started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Barclays began coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.63.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 51.4% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares in the last quarter. Menora Mivtachim Holdings LTD. raised its stake in Teva Pharmaceutical Industries by 31.9% during the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock worth $645,148,000 after buying an additional 9,303,978 shares during the period. Phoenix Financial Ltd. boosted its holdings in Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after acquiring an additional 9,094,372 shares in the last quarter. Soundwatch Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $143,533,000. Finally, Wellington Management Group LLP grew its stake in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after acquiring an additional 6,878,304 shares during the period. 54.05% of the stock is owned by institutional investors.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Goldman Sachs raised its price target on TEVA to $35 and reiterated a “buy” rating, signaling Wall Street conviction in upside versus the current level. Goldman Sachs price target raise
• Positive Sentiment: Additional analyst support: JPMorgan, BofA and Barclays have recently increased targets/ratings (JPMorgan to $35, BofA to $32, Barclays initiating overweight), which likely helped lift sentiment and buying interest. Analyst notes
• Positive Sentiment: Teva’s U.S. affiliate and Alvotech reached a settlement and license with Regeneron setting a U.S. launch window for AVT06 (a proposed biosimilar to Eylea) in Q4 2026 (or earlier under certain conditions) — this reduces launch uncertainty and creates a clearer commercialization timeline. Alvotech settlement
• Neutral Sentiment: Institutional activity is mixed but notable: several funds increased stakes (e.g., Hudson Bay Capital bought more), supporting the view that institutions are accumulating at current levels. Institutional trading
• Neutral Sentiment: Coverage pieces from Zacks and The Motley Fool highlight TEVA as a value/long-term holding — these narrative articles may attract retail interest but are less likely to move price materially on their own. Zacks coverage
• Negative Sentiment: Insider selling: CAO Amir Weiss sold 12,300 shares and Director Roberto Mignone sold 77,400 shares in mid-December at ~\$30.20–30.24 — sizable disclosed sales that may concern some investors about near-term insider conviction. Insider sales

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.